Targeted Therapy
Approved for: NSCLC
Biomarker: ALK
Lorlatinib (Lorbrena) is a FDA-approved treatment for non-small cell lung cancer (NSCLC) that is ALK positive and has metastasized (spread to other parts of the body). It is used in patients whose disease got worse after treatment with: Crizotinib and at least one other ALK inhibitor therapy for metastatic disease, or Alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
In March, 2021 also approved to include frontline treatment for patients with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC.
